We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Circuit Reverses PTAB Ruling on Tarceva Patent
Federal Circuit Reverses PTAB Ruling on Tarceva Patent
In a win for OSI Pharmaceuticals, the U.S. Court of Appeals for the Federal Circuit reversed a ruling by the Patent Trial and Review Board that overturned OSI’s patent for non-small cell lung cancer drug Tarceva (erlotinib).